Selecta Biosciences – Organic Acidemia Association

Update - August 2023

Selecta will pause further development of its wholly-owned gene therapy programs, including the ongoing Phase 1/2 clinical trial of SEL-302, an AAV gene therapy combined with ImmTOR for the treatment of methylmalonic acidemia (MMA). The Company is currently assessing ways to support further development of these programs through potential partnerships.

Overview

Selecta Biosciences is a clinical stage biotechnology company with a commitment to solving the challenges associated with autoimmunity and unwanted immunogenicity through our pioneering ImmTOR^® precision immune tolerance platform.

Research & Studies

NIH Protocol Details – A Phase 1/2, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 following administration of SEL-110) in Pediatric Subjects with Mut Subtype Isolated Methylmalonic Acidemia (MMA)

The reiMMAgine trial is a Phase 1/2 study which aims to investigate how children diagnosed with mut subtype isolated MMA respond to the gene therapy SEL-302 (a combination of SEL-110 and MMA-101), and if the study medication will help with their symptoms.

Articles from previous OAA newsletters:

Successful Gene Therapy Treatment and Redosing in an Animal Model of Methylmalonic Acidemia

Contact Us

Website: https://selectabio.com/

Select Language